These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10935731)

  • 1. [Surrogate end points].
    Bobbio M
    Ital Heart J Suppl; 2000 Jul; 1(7):877-9. PubMed ID: 10935731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of the results of clinical trials: surrogate end points and composite end points.
    Gensini GF; Conti AA
    Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["Soft" and "hard" end points in the example of hypertension].
    Düsing R
    Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S21-6. PubMed ID: 16688661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
    Cooper R; Kaanders JH
    Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
    Legro RS; Myers E
    Hum Reprod; 2004 Aug; 19(8):1697-704. PubMed ID: 15192061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate end points for pulmonary arterial hypertension.
    Kawut SM; Palevsky HI
    Am Heart J; 2004 Oct; 148(4):559-65. PubMed ID: 15459583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new and rapid scoring system to assess the scientific evidence from clinical trials.
    Silber S
    J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.
    Morganti A
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S141-4. PubMed ID: 16565239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill S; Sargent D
    Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
    Mahaffey KW; Roe MT; Kilaru R; French JK; Alexander JH; Berdan LG; Van De Werf F; Simoons ML; Weaver WD; White HD; Lincoff AM; Kleiman NS; Topol EJ; Harrington RA
    Am J Cardiol; 2005 Jun; 95(12):1404-8. PubMed ID: 15950560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global ranking approach to end points in trials of mechanical circulatory support devices.
    Felker GM; Anstrom KJ; Rogers JG
    J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.